Prognostic relevance of uncommon ovarian histology in women with stage III/IV epithelial ovarian cancer
- PMID: 20683400
- DOI: 10.1111/IGC.0b013e3181dd0110
Prognostic relevance of uncommon ovarian histology in women with stage III/IV epithelial ovarian cancer
Abstract
Background: The prognostic relevance of uncommon epithelial ovarian cancer (EOC) histological subtypes remains controversial. The Gynecologic Cancer InterGroup (GCIG) initiated this meta-analysis to assess the relative prognosis of women with a diagnosis of rare EOC histologies from completed, prospectively randomized studies performed by cooperative GCIG study groups.
Methods: Studies eligible for analysis included first-line treatment of at least 150 patients with stage III/IV EOC treated with a platinum/taxane-based regimen. Collaborating groups were to provide patient-level data. Serous acted as the reference histology, and a proportional hazards model was used to estimate the relative rate of progression or death.
Results: Data on 8704 women with stage III/IV EOC from 7 randomized trials were included in these analyses. Two hundred twenty-one patients (2.5%) had clear cell carcinoma; 264 (3.0%), mucinous; and 36 (0.4%), transitional cell. The mean age of patients with serous histology was greater than those with mucinous (4.1 years) and clear cell (2.6 years, P < 0.001). Mucinous, clear cell, and transitional cell tumors were more likely to be completely resected than serous (P < 0.05). When controlling for age and residual disease, mucinous and clear cell tumors had shorter times to progression (hazards ratio [HR], 2.1; 95% confidence interval [CI], 1.8-2.4 and HR, 1.6; 95% CI, 1.4-1.9, respectively) and death (HR, 2.7; 95% CI, 2.3-3.1 and HR, 2.2; 95% CI, 1.8-2.6, respectively) compared with serous. The median overall survival for serous, clear cell, mucinous, and endometrioid histologies were 40.8, 21.3, 14.6, and 50.9 months.
Conclusions: Mucinous and clear cell carcinomas are independent predictors of poor prognosis in stage III/IV EOC. Studies targeting these rare histological subtypes are warranted and will require significant intergroup collaboration.
Similar articles
-
Oncologic outcome after recurrence in patients with stage I epithelial ovarian cancer: are clear-cell and mucinous histological types a different entities?Eur J Obstet Gynecol Reprod Biol. 2014 Oct;181:305-10. doi: 10.1016/j.ejogrb.2014.07.046. Epub 2014 Aug 20. Eur J Obstet Gynecol Reprod Biol. 2014. PMID: 25203309
-
Associations between residual disease and survival in epithelial ovarian cancer by histologic type.Gynecol Oncol. 2017 Nov;147(2):250-256. doi: 10.1016/j.ygyno.2017.08.003. Epub 2017 Aug 16. Gynecol Oncol. 2017. PMID: 28822556
-
CA-125 level as a prognostic indicator in type I and type II epithelial ovarian cancer.Int J Gynecol Cancer. 2013 Jun;23(5):815-22. doi: 10.1097/IGC.0b013e31828f7a24. Int J Gynecol Cancer. 2013. PMID: 23669443 Free PMC article.
-
Uptake and Outcomes of Neoadjuvant Chemotherapy Among US Patients With Less Common Epithelial Ovarian Carcinomas.JAMA Netw Open. 2023 Jun 1;6(6):e2318602. doi: 10.1001/jamanetworkopen.2023.18602. JAMA Netw Open. 2023. PMID: 37326992 Free PMC article.
-
Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis.Pathology. 2011 Aug;43(5):420-32. doi: 10.1097/PAT.0b013e328348a6e7. Pathology. 2011. PMID: 21716157 Review.
Cited by
-
Targeting glutamine dependence through GLS1 inhibition suppresses ARID1A-inactivated clear cell ovarian carcinoma.Nat Cancer. 2021 Feb;2(2):189-200. doi: 10.1038/s43018-020-00160-x. Epub 2021 Jan 11. Nat Cancer. 2021. PMID: 34085048 Free PMC article.
-
Biomarker-based ovarian carcinoma typing: a histologic investigation in the ovarian tumor tissue analysis consortium.Cancer Epidemiol Biomarkers Prev. 2013 Oct;22(10):1677-86. doi: 10.1158/1055-9965.EPI-13-0391. Epub 2013 Jul 23. Cancer Epidemiol Biomarkers Prev. 2013. PMID: 23880734 Free PMC article.
-
Histotype classification of ovarian carcinoma: A comparison of approaches.Gynecol Oncol. 2018 Oct;151(1):53-60. doi: 10.1016/j.ygyno.2018.08.016. Epub 2018 Aug 16. Gynecol Oncol. 2018. PMID: 30121132 Free PMC article.
-
Tubo-Ovarian Transitional Cell Carcinoma and High-grade Serous Carcinoma Show Subtly Different Immunohistochemistry Profiles.Int J Gynecol Pathol. 2019 Nov;38(6):552-561. doi: 10.1097/PGP.0000000000000538. Int J Gynecol Pathol. 2019. PMID: 30059451 Free PMC article.
-
[Histological grading of epithelial ovarian cancer. Review and recommendation].Pathologe. 2014 Sep;35(5):497-503. doi: 10.1007/s00292-014-1948-5. Pathologe. 2014. PMID: 25069848 Review. German.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical